P. Meeus Archives

The coincidence of a Janus Kinase 2 (JAK2) V617F positive myeloproliferative neoplasm (MPN) and a BCR-ABL1 positive chronic myeloid leukaemia (CML) is rare. We present a patient whose bone marrow and peripheral blood showed typical features of essential thrombocytemia (ET). However, the normalisation of the white blood cell (WBC) count after therapy with imatinib for a gastrointestinal stromal tumour (GIST) suggests that an underlying CML was masked, as witnessed by the very low levels of BCR-ABL1 at the haematological diagnosis. The question remains if this is a case of two separate myeloid malignancies or a secondary event (BCR-ABL1 fusion) in a primary JAK2 V617F + ET.

(BELG J HEMATOL 2012:3:105–107)

P. Meeus MD

Articles

P08 RESOLVING DOAC INTERFERENCE ON APTT, PT AND LUPUS ANTICOAGULANT TESTING BY THE USE OF ACTIVATED CARBON

P50 Resolving DOAC interference on lupus anticoagulant testing: evaluation of DOAC-Stop®

A-139 COMPARISON OF 4T-SCORE AND LABORATORY TESTS IN THE DIAGNOSIS OF HIT

A-141 INTERFERENCE OF CRP IN LUPUS ANTICOAGULANS TESTING: IS CRP THE ONLY CAUSE?

The order of draw: much ado about nothing?

P4.03 Introduction of Type and Screen testing in patients from the hematology and oncology department: comparison with blood cross-matching

Concomitant JAK2 V617F positive essential thrombocytemia and BCR-ABL1 positive chronic myeloid leukaemia masked by imatinib therapy for a gastrointestinal stromal tumour

Summary